Supplementing Cancer?

Kenneth D Swanson; Bin Zheng

doi:10.1016/j.molcel.2018.02.036

Supplementing Cancer?

Mol Cell. 2018 Mar 15;69(6):917-918. doi: 10.1016/j.molcel.2018.02.036.

Authors

Kenneth D Swanson¹, Bin Zheng²

Affiliations

¹ Brain Tumor Center and Neuro-Oncology Unit, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: kswanson@bidmc.harvard.edu.
² Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: bin.zheng@cbrc2.mgh.harvard.edu.

PMID: 29547718
DOI: 10.1016/j.molcel.2018.02.036

Abstract

In this issue of Molecular Cell, Lin et al. (2018) report that chondroitin-4-sulfate, which is found in a common supplement meant to alleviate degenerative joint disorders, promotes the growth of BRAF V600E mutant melanoma. This study not only has implications for patient care but also sheds light on a novel mechanism for regulating phosphoinositide 3-kinase signaling.

Publication types

Comment

MeSH terms

Cell Line, Tumor
Chondroitin Sulfates
Dietary Supplements
Humans
Melanoma
Phosphatidylinositol 3-Kinases*
Proto-Oncogene Proteins B-raf*
Sulfates

Substances

Sulfates
Chondroitin Sulfates
Phosphatidylinositol 3-Kinases
BRAF protein, human
Proto-Oncogene Proteins B-raf